Higher CMAHP expression was associated with better patient OS in lung adenocarcinoma (LUAD, log-rank test, p = 0.00142)) and cutaneous melanoma (SKCM, log-rank test, p = 7.47 × 10−6), respectively (Fig. 6D). Here, CMAHP is linked to lung adenocarcinoma.